Open AccessOvercoming obstacles to repurposing for neurodegenerative disease
Author(s) -
Shineman Diana W.,
Alam John,
Anderson Margaret,
Black Sandra E.,
Carman Aaron J.,
Cummings Jeffrey L.,
Dacks Penny A.,
Dudley Joel T.,
Frail Donald E.,
Green Allan,
Lane Rachel F.,
Lappin Debra,
Simuni Tanya,
Stefanacci Richard G.,
Sherer Todd,
Fillit Howard M.
Publication year - 2014
Publication title -
annals of clinical and translational neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.824
H-Index - 42
ISSN - 2328-9503
DOI - 10.1002/acn3.76
Subject(s) - repurposing , medicine , food and drug administration , drug repositioning , reimbursement , stakeholder , drug approval , government (linguistics) , approved drug , foundation (evidence) , disease , alternative medicine , advisory committee , drug , pharmacology , public relations , public administration , pathology , health care , political science , ecology , linguistics , philosophy , law , biology
Repurposing Food and Drug Administration ( FDA )‐approved drugs for a new indication may offer an accelerated pathway for new treatments to patients but is also fraught with significant commercial, regulatory, and reimbursement challenges. The Alzheimer's Drug Discovery Foundation ( ADDF ) and the Michael J. Fox Foundation for Parkinson's Research ( MJFF ) convened an advisory panel in October 2013 to understand stakeholder perspectives related to repurposing FDA ‐approved drugs for neurodegenerative diseases. Here, we present opportunities on how philanthropy, industry, and government can begin to address these challenges, promote policy changes, and develop targeted funding strategies to accelerate the potential of FDA ‐approved repurposed drugs.